NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS.
ARGX: Shares Float is 32.09M
Technicals : The MA(9) has solidly passed the EMA(60) putting it into bullish territory. The stock price is also in the midst of making up the gap down that occurred in early August. IMO, the next resistance is close to the $5.00 level.
News: A women’s health specialty pharmaceutical company, announced that Al Altomari, Chairman and CEO, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26th, 2017 at 11:30 AM Eastern Time in New York City.
In addition, an abstract presenting data from the Phase 3 SECURE study of its investigational low-dose combined hormonal contraceptive patch (AG200-15) has been selected for an oral presentation during the American Society for Reproductive Medicine (ASRM) Annual Congress being held October 28th – November 1st, 2017 in San Antonio, TX.
CRMD: Shares Float of 54.68.
Technicals: The RSI(14) and the MACD are both inching their way up to being bullish and we may see another big gain on Monnday accordinal tio the technical indicators.
News: CRMD, a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, will present at this year's MicroCap Conference at 2:00 PM ET on October 5, 2017, in New York City. Chief Executive Officer Khoso Baluch will provide an overview of the company's business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
DRRX: Shares float of 140.73M
Technicals: Price forming a U-shape up to $1.90 where it will either continue as a cup and handle pattern or continue strongly past 1.90. On the weekly chart, the next resistance level is showing at $2.09.
News: James E. Brown, President and CEO, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 at 3:00 pm Eastern Time. The conference is being held at the InterContinental New York Barclay Hotel.
A development and commercialization agreement, announced on May 8th, with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. This agreement has doubled the stock price since May 8th and IMO, the price will continue its upward trend into Q1 of 2018 when Durect resubmits the NDA and get approval for Posimir.
SYN: Shares float of 125.76M
Technicals - This stock has become a regular on the watchlist of late as it has been trending up for the past 4 - 5 weeks. Looking at the attached weekly chart, there does not seem to be much resistance up to $1.60, IMO, which is 60% higher than Friday's close. The volume has started to pick up substantially as technical indicators turn bullish.
News - Recent news reflects the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging.
VIVE: Shares float of 17.78M.
Technicals - Strong price movement on Friday pushed it passed the resistance of $5.96. If it holds, the next level would be $7.04. This stock is one to watch carefully as it may continue to consolidate for a few more days before the next big uptrend starts.
News - The impact of the September 12th NR was slow to affect the stock price but it might be starting. The NR announced that the company has received regulatory approvals for the Viveve® System in Bahrain, Kuwait, and Qatar. The Viveve System, that delivers the Geneveve Treatment, is cleared for marketing as a treatment of the vaginal introitus to improve vaginal laxity.
In addition, Patricia Scheller, chief executive officer, will present at the 2017 Ladenburg Thalmann Healthcare Conference, on Tuesday, September 26th at 9:30AM ET in New York City. Ms. Scheller will provide an update of the Company's global development and commercialization of the GENEVEVE™ Treatment and InControl Products by Viveve.